Search results for "SCAR"

showing 10 items of 914 documents

Introduction

2016

This collection of essays is a tribute to Neri Salvadori, the man and scholar, teacher and friend, whom the scientific community owes important works in the tradition of Piero Sraffa’s revival of the classical economists’ approach to the problems of value, income distribution, capital accumulation, technical progress, scarce natural resources, economic development and growth. The essays in this book have all been freshly written and contain original work with novel ideas in the areas mentioned. In this introduction we first summarize briefly Neri Salvadori’s academic career, his work and his intellectual and organisational activities and then provide a short overview of the essays collected…

Neri Salvadori Piero Sraffa value income distribution capital accumulation scarce natural resources growthSettore SECS-P/04 - Storia Del Pensiero EconomicoSettore SECS-P/01 - Economia Politica
researchProduct

Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.

2000

Abstract One of the most prominent cholinergic deficit in Alzheimer’s disease (AD) is the reduced number of nicotinic acetylcholine receptors (nAChR) in the hippocampus and cortex of AD patients, as compared to age-matched controls. This deficit results in reduced nicotinic cholinergic excitation which may not only impair postsynaptic depolarization but also presynaptic neurotransmitter release and Ca 2+ -dependent intracellular signaling, including transcriptional activity. Presently, the most common approach to correct the nicotinic cholinergic deficit in AD is the application of cholinesterase inhibitors. Due to the resulting increase in synaptic acetylcholine levels, both in concentrati…

NeuronsPatch-Clamp TechniquesBiologyNeurotransmissionReceptors NicotinicSynaptic TransmissionCell LineBehavioral NeuroscienceNicotinic acetylcholine receptorMiceGanglion type nicotinic receptorNicotinic agonistAllosteric RegulationAlzheimer DiseaseMuscarinic acetylcholine receptormedicineAnimalsHumansNicotinic AgonistsAlpha-4 beta-2 nicotinic receptorNeuroscienceAcetylcholine5-HT receptorAllosteric Sitemedicine.drugBehavioural brain research
researchProduct

Desensitization is a property of the cholinergic binding region of the nicotinic acetylcholine receptor, not of the receptor-integral ion channel

1991

AbstractThe reversible acetylcholine esterase inhibitor (−)-physostigmine (eserine) is the prototype of a new class of nicotinic acetylcholine receptor (nAChR) activating ligands: it induces cation fluxes into nAChR-rich membrane vesicles from Torpedo marmorala electric tissue even under conditions of antagonist blocked acetylcholine binding sites (Okonjo, Kuhlmann, Maclicke, Neuron, in press). This suggests that eserine exerts its channel-activating property via binding sites at the nAChR separate from those of the natural transmitter. We now report that eserine can activate the channel even when the receptor has been preincubated (desensitized) with elevated concentrations of acetylcholin…

Nicotinic acetylcholine receptorStereochemistryAcetylcholine-gated cation channelPhysostigmineBiophysicsCesiumIon fluxDesensitizationIn Vitro TechniquesReceptors NicotinicTorpedoBiochemistryIon ChannelsAnticholinesteraseAcetylcholine bindingGanglion type nicotinic receptorStructural BiologyMuscarinic acetylcholine receptor M5GeneticsmedicineAnimalsMolecular BiologyAcetylcholine receptorBinding SitesChemistryCell BiologyBungarotoxinsAcetylcholineNicotinic acetylcholine receptorNicotinic agonistCarbamateBiophysicsCholinergicAcetylcholineEserinemedicine.drugFEBS Letters
researchProduct

Activation of Muscarinic Receptors by Non-neuronal Acetylcholine

2011

The biological role of acetylcholine and the cholinergic system is revisited based particularly on scientific research early and late in the last century. On the one hand, acetylcholine represents the classical neurotransmitter, whereas on the other hand, acetylcholine and the pivotal components of the cholinergic system (high-affinity choline uptake, choline acetyltransferase and its end product acetylcholine, muscarinic and nicotinic receptors and esterase) are expressed by more or less all mammalian cells, i.e. by the majority of cells not innervated by neurons at all. Moreover, it has been demonstrated that acetylcholine and “cholinergic receptors” are expressed in non-neuronal organism…

Nicotinic agonistChemistryMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M5medicineMuscarinic acetylcholine receptor M4Muscarinic acetylcholine receptor M3CholinergicMuscarinic acetylcholine receptor M2Acetylcholinemedicine.drugCell biology
researchProduct

Effects of ouabain on human bronchial muscle in vitro

2003

The effects of ouabain, an inhibitor of the plasmalemmal Na(+)/K(+)-ATPase activity, were examined in human isolated bronchus. Ouabain produced concentration-dependent contraction with -logEC(50)=7.16+/-0.11 and maximal effect of 67+/-4% of the response to acetylcholine (1 mM). Ouabain (10 microM)-induced contraction was epithelium-independent and was not depressed by inhibitors of cyclooxygenase and lipoxygenase, antagonists of muscarinic, histamine H(1)-receptors and alpha-adrenoceptors, or neuronal Na(+) channel blockade. The inhibition of ouabain contraction in tissues bathed in K(+)-free medium, and the inhibition by ouabain of the K(+)-induced relaxation confirm that the contractile a…

NitroprussideCromakalimmedicine.medical_specialtySodium-Hydrogen ExchangersTime FactorsInositol PhosphatesMuscle RelaxationVasodilator AgentsBronchiIn Vitro TechniquesOuabainMembrane Potentialschemistry.chemical_compoundSodium Potassium Chloride Symporter InhibitorsInternal medicineMuscarinic acetylcholine receptormedicineHumansVasoconstrictor AgentsNa+/K+-ATPaseOuabainInositol phosphateProtein Kinase CPharmacologychemistry.chemical_classificationForskolinColforsinIsoproterenolMuscle SmoothGeneral MedicineCalcium Channel BlockersAcetylcholineAmilorideEndocrinologychemistryCalciumSodium-Potassium-Exchanging ATPaseHistamineAcetylcholineHistaminemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Imaging Findings in Non-Cirrhotic Liver

2011

With the widespread use of cross-sectional imaging examinations, physicians from a wide array of specialties are becoming involved with questions regarding the management of patients with focal liver lesions. To formulate a practical approach to these patients, several factors must be incorporated into a clinical decision-making algorithm, including the clinical setting (e.g., known comorbidities, underlying cirrhosis or a known primary neoplasm), the presence of clinical signs and symptoms, the results of laboratory tests, and the critical information provided by imaging studies. In this chapter, we will briefly review important technical factors for optimization of CT protocols for the ev…

Non cirrhotic livermedicine.medical_specialtyCirrhosisbusiness.industryFocal nodular hyperplasiaSigns and symptomsKey featuresmedicine.diseasePrimary NeoplasmHepatic arterial infusion chemotherapymedicineCentral ScarRadiologybusiness
researchProduct

Designing robust immediate release tablet formulations avoiding food effects for BCS class 3 drugs

2019

Abstract Food induced viscosity in the gastrointestinal tract is reported to reduce the bioavailability of tablets containing BCS class 3 drugs, mainly by retarding their disintegration and dissolution of the active pharmaceutical ingredient. The role of formulation factors in minimizing this negative food effect is largely unknown. Combinations of disintegrants were studied together with soluble and insoluble fillers and trospium chloride as model drug substance. Different batches of tablets were compressed at 10 kN and 30 kN, by incorporating different combinations of croscarmellose sodium (CSS), cross-linked (CPD) and sodium starch glycolate (SSG) at low level i.e, 2% + 2% and high level…

NortropanesChemistry PharmaceuticalDrug CompoundingPharmaceutical Science02 engineering and technologyBenzilates030226 pharmacology & pharmacyExcipientsFood-Drug Interactions03 medical and health sciencesViscositychemistry.chemical_compound0302 clinical medicineFood scienceSolubilityLactoseDissolutionActive ingredientCroscarmellose sodiumViscosityChemistryGeneral Medicine021001 nanoscience & nanotechnologyBioavailabilityMicrocrystalline celluloseDrug LiberationSolubilityDrug Design0210 nano-technologyTabletsBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Precision Measurement of the Mass and Lifetime of the Ξ[0 over b] Baryon

2014

Using a proton-proton collision data sample corresponding to an integrated luminosity of 3 fb$^{-1}$ collected by LHCb at center-of-mass energies of 7 and 8 TeV, about 3800 $\Xi_b^0\to\Xi_c^+\pi^-$, $\Xi_c^+\to pK^-\pi^+$ signal decays are reconstructed. From this sample, the first measurement of the $\Xi_b^0$ baryon lifetime is made, relative to that of the $\Lambda_b^0$ baryon. The mass differences $M(\Xi_b^0)-M(\Lambda_b^0)$ and $M(\Xi_c^+)-M(\Lambda_c^+)$ are also measured with precision more than four times better than the current world averages. The resulting values are $\frac{\tau_{\Xi_b^0}}{\tau_{\Lambda_b^0}} = 1.006\pm0.018\pm0.010$, $M(\Xi_b^0) - M(\Lambda_b^0) = 172.44\pm0.39\pm…

Nuclear TheoryAnalytical chemistryGeneral Physics and Astronomyinclusive weak decays; discarding 1/N(C); beaty; charm; ruleLambdaHigh Energy Physics - Experimenthigh energy physicsSettore FIS/04 - Fisica Nucleare e Subnucleare[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]INCLUSIVE WEAK DECAYS; DISCARDING 1/N(C); BEAUTY; CHARM; RULENuclear ExperimentQCPhysicsprecision measurementPhysicsintegrated luminosityParticle physicsBEAUTYtransverse momentaPseudorapidityPhysical SciencesTransverse momentumINCLUSIVE WEAK DECAYSFísica nuclearLHC13.30.Egtellurium compoundsParticle Physics - Experiment530 PhysicsAstrophysics::High Energy Astrophysical PhenomenaPhysics MultidisciplinarypseudorapiditiesPhysics InstituteLHCb - Abteilung HofmannAstrophysics::Cosmology and Extragalactic AstrophysicsCHARMNuclear physicsPhysics and Astronomy (all)Pi14.20.MrScience & Technologycenter-of-mass energiesmass differencetransverse momenta; precision measurement; center-of-mass energies; tellurium compounds; production rates; pseudorapidities; high energy physics; integrated luminosity; hadrons; mass difference; proton proton collisionsDISCARDING 1/N(C)BaryonLHCbproton proton collisionshadronsHadronic decays of baryonBottom baryons (|B|>0)Physics::Accelerator Physicsproduction ratesFísica de partículesExperimentsRULE
researchProduct

Seasonal cues to food scarcity and calorie cravings: Winter cues elicit preferences for energy-dense foods

2021

Abstract Winter cues signal a scarcity of food. Birds and mammals respond to such environmental cues by consuming more energy. They convert this surplus into body fat that serves as a buffer against impending food shortages. Similarly, humans exhibit higher obesity rates among food-insecure populations. However, to date, it has been unclear whether winter cues qualitatively affect consumers’ food preferences. Results from five studies ( N = 865), with one of them preregistered, show that watching videos depicting winter cues elicits thoughts about energy-dense foods and survival. Such cues elicit higher preferences for energy-dense than low-calorie foods, as verified by meta-analytic eviden…

Nutrition and DieteticsCaloriemedia_common.quotation_subjectEnergy (esotericism)Economic shortagemedicine.diseaseAffect (psychology)ObesityScarcityEnvironmental healthmedicinePsychologySensory cueFood scarcityFood Sciencemedia_common
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct